[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344661-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-344661-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","management-of-bartholins-gland-carcinoma-in-a-perimenopausal-woman-a-case-report","Management of Bartholin’s Gland Carcinoma in a Perimenopausal Woman - A Case Report","","Management of Bartholin’s gland carcinoma in a perimenopausal woman is described through a clinical case. A 53-year-old patient with a palpable right labial nodule and vulvar discomfort underwent surgical tumor removal, followed by paclitaxel–carboplatin chemotherapy and adjuvant radiotherapy. Imaging 6 months after treatment showed no recurrence. Molecular and biochemical monitoring included HPV testing and repeated assessment of CEA and CA 19-9 across multiple time points. Histology confirmed the diagnosis, with treatment producing expected outcomes and lower tumor marker levels after therapy than at diagnosis.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/management-of-bartholins-gland-carcinoma-in-a-perimenopausal-woman-a-case-report/344661/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/management-of-bartholins-gland-carcinoma-in-a-perimenopausal-woman-a-case-report/344661.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What treatment was administered for Bartholin’s gland carcinoma in this case?","Question",{"text":62,"@type":63},"The tumor was surgically removed, followed by paclitaxel and carboplatin chemotherapy and adjuvant radiotherapy.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were tumor response and remission monitored?",{"text":67,"@type":63},"CEA and CA 19-9 levels were measured repeatedly across defined time points, showing significantly lower levels after chemotherapy and radiotherapy than at diagnosis.",{"name":69,"@type":60,"acceptedAnswer":70},"What were the HPV findings in the tumor sample?",{"text":71,"@type":63},"No HPV genotypes were detected in the tumor, and the patient reported no history of HPV infection.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},344661,1790193374,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":96,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","e-ISSN 1941-5923  \n© Am J Case Rep, 2026; 27: e951359 DOI: 10. 12659/AJCR.951359  \nReceived: 2025.09.02  \nAccepted: 2025.10.23  \nAvailable online: 2025.12.04  \nPublished: 2026.01.22  \nAuthors’ Contribution: Study Design A  \nData Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G  \nABCDE 1 B 2  \nC 3-5 E 3,6,7 F 7  \nE 3  \nF 4,8  \nE 3,9  \nCorresponding Author: Financial support: Conflict of interest:  \nManagement of Bartholin’s Gland Carcinoma in a Perimenopausal Woman: A Case Report  \nPrzemysław Borawski Robert Kulhawik  Dariusz Boroń  Tomasz Sirek  Kacper Boroń  \nPiotr Ossowski Marcin Opławski   \nBeniamin Oskar Grabarek   \n1 Voivodeship Specialist Hospital, Włocławek, Poland  \n2 Sexology and Pathology Clinic, Warsaw, Poland  \n3 Collegium Medicum, WSB University, Dąbrowa Górnicza, Poland  \n4 Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Cracow, Poland  \n5 Department of Gynecology and Obstetrics, TOMMED Specjaliści od Zdrowia, Katowice, Poland  \n6 Department of Plastic and Reconstructive Surgery, Hospital for Minimally Invasive and Reconstructive Surgery in Bielsko-Biała, Bielsko-Biała, Poland  \n7 Department of Plastic Surgery, Faculty of Medicine, Academy of Silesia, Katowice, Poland  \n8 Department of Gynecology and Obstetrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University in Cracow, Cracow, Poland  \n9 Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University in Cracow, Cracow, Poland  \nPrzemysław Borawski, e-mail: [przembor3@gmail.com](przembor3@gmail.com)  \nNone declared  \nNone declared  \nPatient: Female, 53-year-old  \nFinal Diagnosis: Bartholin’s gland cancer  \nSymptoms: Palpable nodule in right labia majora • vulvar discomfort  \nClinical Procedure: —  \nSpecialty: Obstetrics and Gynecology  \nObjective: Rare disease  \nBackground: Bartholin’s gland carcinoma represents less than 5% of all vulvar cancers and is typically identified in postmenopausal women. We present a case involving a 53-year-old woman with primary Bartholin’s gland carcinoma.  \nCase Report: Treatment included surgical removal of the tumor, followed by chemotherapy with paclitaxel and carboplatin and adjuvant radiotherapy. Imaging studies 6 months after treatment showed no evidence of recurrence. The patient died 5 years after cancer diagnosis due to coronavirus infection. Molecular and biochemical analyses included human papillomavirus (HPV) testing and evaluation of changes in carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9) levels before lesion excision (time 0), before curettage of the uterine cavity and cervical canal (time 1), before radical lesion excision (time 2), before chemotherapy (time 3) and radiotherapy (time 4), and at 6 months after treatment completion (time 5). Histological analysis confirmed the diagnosis of Bartholin’s gland carcinoma. The implemented treatment produced expected results. No HPV genotypes were detected in the tumor sample, and the patient had no history of HPV infection. Significantly (P\u003C0.05) higher CEA and CA 19-9 levels were observed in the preoperative period compared with remission. Tumor marker levels were significantly lower after chemotherapy and radiotherapy than at diagnosis.  \nConclusions: Paclitaxel–carboplatin chemotherapy with radiotherapy produced expected outcomes. CEA and CA 19-9 may serve as useful markers of treatment response and cancer remission. Genomic or RNA sequencing and HPV genotyping of tumor samples are advisable, given the absence of a well-defined molecular profile for Bartholin’s gland carcinoma.  \nKeywords: Bartholin’s Glands • Chemotherapy, Cancer, Regional Perfusion • High-Throughput Nucleotide Sequencing • Radiotherapy  \nFull-text PDF: [https://www.amjcaserep.com/abstract/index/idArt/951359](https://www.amjcaserep.com/abstract/index/idArt/951359)  \n1212  2  1  21  \nPublisher’s note: All c","cbCaiegVrRwulXMx","https://ap.wps.com/l/cbCaiegVrRwulXMx","pdf",1402991,"English","# Introduction\n## Case Report\n## Conclusions","[{\"question\":\"What treatment was administered for Bartholin’s gland carcinoma in this case?\",\"answer\":\"The tumor was surgically removed, followed by paclitaxel and carboplatin chemotherapy and adjuvant radiotherapy.\"},{\"question\":\"How were tumor response and remission monitored?\",\"answer\":\"CEA and CA 19-9 levels were measured repeatedly across defined time points, showing significantly lower levels after chemotherapy and radiotherapy than at diagnosis.\"},{\"question\":\"What were the HPV findings in the tumor sample?\",\"answer\":\"No HPV genotypes were detected in the tumor, and the patient reported no history of HPV infection.\"}]","Management of Bartholin’s Gland Carcinoma in a Perimenopausal Woman - A Case Report | PDF",1790054783,13]